PNAS 2012: "In certain cases mass vaccination can have the counterproductive effect of allowing an increase in severe disease, through reducing opportunities for immunity to be boosted through natural exposure to infection"
This is almost prophetic
"Even booster schedules do not offer a reliable means of maintaining herd immunity. On the other hand, boosting may instead be supplied through natural exposure to infection, in which case vaccination may in fact reduce existing herd immunity."
"B. pertussis, for example, it has recently been proposed that mass immunization, eliciting waning immunity, may have reduced opportunities for natural boosting to occur, thus permitting an increase in overall disease incidence"
"The blue curve represents a vaccination program that continues indefinitely, whereas the red curve represents a program that is discontinued once local elimination of infection is first achieved. Even indefinite vaccination will not maintain herd immunity."
"The black curve illustrates the results of mass immunization, using a conventional vaccine. Despite 95% vaccine coverage, herd immunity is impermanent and there is ultimately a resurgence of infection as vaccinated individuals eventually rejoin the susceptible pool."
"Beyond a certain point, increasing vaccination coverage can be seen to increase overall disease in the population."
"In turn, these cycles emerge where vaccination reduces the force of infection to such an extent as to compromise the potential for natural boosting to occur."
"The models we present here also offer a cautionary tale: When reexposure is necessary to maintain immunity, a reactivating vaccine that offers virtually life-long individual-level protection can cause unvaccinated individuals to suffer increased disease incidence."
"This raises ethical concerns in situations where a subset of the population is unable to receive successful vaccination, whether due to genetics, cultural practices, or access to health-care services."
"The waning of natural and vaccine-induced immunity poses substantial barriers in the control of many infections, in particular by compromising the buildup of herd immunity in the population."
"Do vaccines provide partial protection to everyone (leaky) or full protection to a subset of the population (all or none)? "
"The consequences of our underlying model assumptions about immunity underscore the need for quantitative studies on the induction, maintenance, and function of immune memory... the relative roles of antigen stimulation and long-lived mem. cells,in the maintenance of immune mem"
"Another key, clinical question is the potential utility of self-boosting vaccines in maintaining mucosal vs. systemic immunity."
By the way, this study was funded by the Bill and Melinda Gates Foundation and the NIH🤔
Sinovac, Universidad Católica, Corrupción y Conflictos de Interés durante el proceso que determinó la elección del ensayo clínico con la vacuna SINOVAC.Este hilo profundiza un hilo anterior sobre la distribución d la vacuna SINOVAC.
¿Hay solo un interés sanitario en todo esto?
Para la determinación y autorización de una vacuna en Chile normalmente el @ministeriosalud trabaja en coordinación con:
- Comité Asesor en Vacunas y Estrategias de Inmunización (CAVEI)
- Programa Nacional de Inmunizaciones (PNI)
- Instituto de Salud Pública @ispch (ISP)
Sin embargo TODAS estas fueron excluidas de la discusión de la Estrategia Nacional para la disponibilidad de la Vacuna COVID-19, encabezada por el Ministerio de Ciencia, Tecnología y el propio @ministeriosalud ha sido reducido a un papel irrelevante.
Nature 2005: "Caution raised over SARS vaccine"
"Jab against one strain might worsen infection with others." nature.com/articles/news0…
"A cautionary note has been sounded for those developing vaccines against severe acute respiratory syndrome (SARS). Some vaccines could prove useless against certain strains, or even worsen the infection, a preliminary study suggests."
"The results show that the virus changes over time, so that a strain that crops up in one outbreak might be quite different from that in a later outbreak. "This virus is not standing still and we need to take this into account," Nabel says."
Este hilo resume los problemas de seguridad y problemas a los que se ha visto enfrentada por 18 años la vacuna de virus inactivado contra el Sars Cov1, Mers y ahora Sars Cov2,ampliamente distribuida por SINOPHARM en muchos países latinoamericanos. ¿Qué tanto se ha avanzado?
Desde la aparición del SARS en 2003 las vacunas inactivadas fueron la 1° opción d desarrollo, pero desde el comienzo demostraron tener problemas serios de seguridad.
Los cuales posiblemente estén ocurriendo hoy en día.
Durante el hilo, observe la progresión d los años.
CDC 2005 Desarrollo de la vacuna contra el SARS:
"La seguridad de la vacuna inactivada es una preocupación seria; algunas proteínas virales pueden inducir respuestas inmunes o inflamatorias dañinas, incluso causando enfermedades SIMILARES al SARS" 🤔
13 May 2013: SARS-Like Virus Vaccine Unlikely, Experts Say
"Health officials said vaccines were unlikely to play a role in controlling the outbreak"
"The thing that really takes time is the regulation aspect of it," said Ksiazek, professor in the dept. of pathology at the Univ. of Texas Medical Branch, describing the lengthy process of proving safety and efficacy in animal models before even thinking about testing in humans."
"There was no vaccine for SARS," Atmar said. "But the public health system was able to control the infection and basically eradicate it. That might also work for this new coronavirus."
SARS vaccines: where are we?
"Data regarding the correlates of protection, animal models and the available evidence regarding potential vaccine ENHANCEMENT of SARS disease are discussed"
Inactivated virus vaccines
"However, despite high neutralizing antibody titers, protection was incomplete for all vaccine preparations and administration routes tested." 🤔@juancarlossaid
AdVs vectored SARS-CoV vaccines
"Interestingly, although the intramuscular route was more effective in inducing neutralizing SARS serum antibodies, the INTRANASAL route of administration induced IgA and was MORE EFFECTIVE in blocking SARS-CoV replication in nose and lung tissue"